{"id":45216,"date":"2022-06-17T15:01:44","date_gmt":"2022-06-17T13:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-herpes-zoster-treatment-market-report-to-2030-players-include-bausch-health-cipla-and-camber-pharmaceuticals-researchandmarkets-com\/"},"modified":"2022-06-17T15:01:44","modified_gmt":"2022-06-17T13:01:44","slug":"global-herpes-zoster-treatment-market-report-to-2030-players-include-bausch-health-cipla-and-camber-pharmaceuticals-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-herpes-zoster-treatment-market-report-to-2030-players-include-bausch-health-cipla-and-camber-pharmaceuticals-researchandmarkets-com\/","title":{"rendered":"Global Herpes Zoster Treatment Market Report to 2030 – Players Include Bausch Health, Cipla and Camber Pharmaceuticals – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Herpes Zoster Treatment Market by Treatment Type Route Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global herpes zoster treatment market was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.\n<\/p>\n

\nHerpes zoster (shingles) is a viral infection, caused due to the varicella-zoster virus. It is usually a painful rash on the skin that causes flickering, torment, and itchy blisters on the back, chest, and face and spreads to The rest of the body. Symptoms typically start with pain along the affected dermatome, which is followed by an enlarged vesicular eruption in 2-3 days. Symptoms include lymph nodes, fever, chills, and headache, itching, raised dots on skin and redness in that area, stabbing or shooting pain, tingling, or burning feeling in or under the skin, and upset stomach.\n<\/p>\n

\nAnyone who gets herpes zoster has a history of chickenpox, often decades earlier. These two conditions come from the same virus, called varicella zoster. In addition, individuals with herpes zoster can infect another person who never had chicken pox, yet the individual will foster chicken pox and not herpes zoster. Herpes zoster is pervasive in older adults as they have weak immune system. Individuals going through radiation treatment or chemotherapy have weakened immune system and are more inclined to get herpes zoster sickness.\n<\/p>\n

\nIn addition, PCR can be used to detect VZV DNA rapidly and sensitively, and is now widely available. After the analysis of herpes zoster, drug is given for treatment, which incorporates oral medications and antibodies. Antihistamines, desensitizing creams, gels, or fixes are given to lessen the agony. Vaccines are given to more established individuals who have a higher risk of acquiring herpes zoster.\n<\/p>\n

\nHerpes zoster occurs due to reactivation of varicella zoster virus in older age and the incidences of herpes zoster is higher in geriatric population compared to adults and children. For instance, in 2021, the U.S. reported that the risk of herpes zoster increases with age. It has been expected that the incidence of herpes zoster in the U.S. will increase with increasing older age population.\n<\/p>\n

\nMoreover, increase in geriatric population, coupled with rising incidences of herpes zoster also contribute toward growth of the market. However, dearth of skilled professionals is expected to hinder growth of the market. Conversely, increase in drug development provides lucrative growth opportunities to the market.\n<\/p>\n

\nKey Benefits<\/strong>\n<\/p>\n